LGVN
Longeveron Inc.
Healthcare — Biotechnology
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
None
3 analysts
$2.59
$-0.10 (-3.72%)
Target:
$7.15
(176.1%)
Price History
52-Week Range
Sign in to add LGVN to a watchlist or set price alerts.
Fundamentals
| Market Cap | $23.04M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.48 |
| EPS (TTM) | $-1.14 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 4.50% |
| ROE | -135.18% |
| Debt/Equity | 4.67 |
| Recommendation | None |
| Analyst Target | $7.15 |
| Analysts | 3 |
| Next Earnings | Aug 12, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 42.5 |
| Beta | -0.38 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $1.80 |
| 52-Week Low | $0.48 |
| 50-Day Avg | $0.80 |
| 200-Day Avg | $0.74 |
| Avg Volume | 45.5K |
| Volume | 61.8K |
Performance Analysis
NEUTRALLGVN presents a mixed picture with both positive and negative indicators.
-
Trading near its 52-week high ($1.80), which may indicate limited upside.
~
RSI at 42.5 is in neutral territory.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
~
Modest revenue growth of 4.5% year-over-year.
~
Wall Street consensus is "none" from 3 analysts.
+
Average analyst target of $7.15 implies 176.1% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:18 UTC
Back to Screener Export Report